Saccharomyces boulardii CNCM I-1079

Saccharomyces boulardii CNCM I-1079 is a specific probiotic yeast strain that modulates gut microbiota composition by promoting short-chain fatty acid (SCFA)-producing bacteria and suppressing pathogenic species. Its primary mechanism involves competitive exclusion of pathogens and stimulation of beneficial commensal bacteria such as Lactobacillus reuteri to support digestive and metabolic health.

Origin & History

Saccharomyces boulardii CNCM I-1079 is a specific strain of the yeast Saccharomyces cerevisiae boulardii, deposited in the Collection Nationale de Cultures de Microorganismes under number I-1079. It is produced through fermentation processes for probiotic supplementation and is commercially available in products like Levucell SB, administered as viable cells measured in colony-forming units (CFUs).

Historical & Cultural Context

No historical or traditional medicine context was identified for Saccharomyces boulardii CNCM I-1079. It is a modern, patented probiotic strain without references to traditional systems.

Health Benefits

• May reduce remnant lipoprotein levels (cholesterol biomarker) based on one pilot study (Preliminary evidence)
• Increases gut bacterial diversity and SCFA-producing bacteria in animal models (Animal evidence only)
• Promotes beneficial bacteria like Lactobacillus reuteri while reducing pathogens like Campylobacter (Animal evidence only)
• Improves intestinal histology including increased villi length and crypt depth (Animal evidence only)
• Limited effectiveness for stress reduction or academic performance in humans (Negative finding from RCT)

How It Works

Saccharomyces boulardii CNCM I-1079 exerts its effects partly through stimulation of secretory IgA (sIgA) and modulation of toll-like receptor (TLR) signaling pathways in intestinal epithelial cells, reducing pro-inflammatory cytokine release. The strain produces proteases that degrade bacterial toxins and adhesins, limiting pathogen colonization of intestinal mucosa. Additionally, by enriching SCFA-producing taxa, it increases luminal concentrations of butyrate and propionate, which serve as histone deacetylase (HDAC) inhibitors and GPR41/GPR43 receptor ligands to regulate lipid metabolism and intestinal barrier integrity.

Scientific Research

Human clinical trials for CNCM I-1079 are limited, with a 30-day RCT in stressed individuals showing no benefit for performance or stress markers (PMID: 32438624) and an 8-week pilot study showing reduced remnant lipoproteins (PMID: 25893960). Most evidence comes from animal studies in calves and chickens, while a related strain CNCM I-3799 showed efficacy for pediatric diarrhea (PMID: 32796401).

Clinical Summary

A pilot human study investigating Saccharomyces boulardii CNCM I-1079 supplementation found a potential reduction in remnant lipoprotein particle levels, a cardiovascular risk biomarker, though the study was small and preliminary in nature with no confirmed sample size published in widely available literature. Animal model studies have demonstrated increased gut bacterial alpha-diversity and enrichment of SCFA-producing genera following supplementation with this strain. Promotion of Lactobacillus reuteri and concurrent reduction in opportunistic pathogens has been documented in preclinical models, but these findings have not yet been replicated in large-scale randomized controlled trials. Overall, the current evidence base is limited to early-phase and animal research, and definitive clinical conclusions cannot yet be drawn.

Nutritional Profile

Saccharomyces boulardii CNCM I-1079 is a probiotic yeast, not a conventional food ingredient, so macronutrient and micronutrient profiling differs from typical dietary components. As a yeast organism, its cell composition includes: Protein: approximately 40-50% of dry cell weight, containing all essential amino acids with particularly notable concentrations of glutamic acid, aspartic acid, and leucine. Carbohydrates: approximately 30-40% of dry cell weight, predominantly as beta-1,3/1,6-glucans (cell wall polysaccharides with immunomodulatory properties) and trehalose (intracellular disaccharide, ~10-15% dry weight, contributing to thermal stability). Lipids: approximately 4-7% of dry cell weight, including ergosterol (a precursor to vitamin D2 upon UV exposure) and phospholipids. Bioactive compounds: produces secretory proteases (notably a 54 kDa serine protease) that cleave bacterial toxins; secretes polyamines (spermidine, putrescine) that support intestinal epithelial cell growth; produces short-chain fatty acids including acetic acid as metabolic byproducts. B-vitamins: as a Saccharomyces species, contains measurable B-vitamins including thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), pyridoxine (B6), and folate (B9), though exact concentrations in this specific strain are not independently published. Minerals: contains zinc, selenium, chromium, and manganese bound within cellular structures, with bioavailability dependent on cell wall integrity and digestive processing. Delivered dose in supplements is typically 5×10^9 CFU per serving; the yeast survives gastric acid (optimal activity pH 4-7) and reaches the intestine viable, with transit-dependent colonization rather than permanent establishment.

Preparation & Dosage

Animal studies used 2.0 × 10^10 CFUs/day for calves and 10^9 CFU/kg feed for chickens. Human studies have used daily supplementation for 30 days (stress) or 8 weeks (cholesterol), though exact CFU counts were not specified. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other probiotic strains, Prebiotics (FOS/GOS), Digestive enzymes, L-glutamine, Zinc carnosine

Safety & Interactions

Saccharomyces boulardii CNCM I-1079 is generally considered safe for healthy adults, consistent with the broader safety profile of the Saccharomyces boulardii species, which has GRAS (Generally Recognized As Safe) status in many jurisdictions. However, immunocompromised individuals, those with central venous catheters, or critically ill patients face a rare but documented risk of fungemia (yeast entering the bloodstream) and should avoid live yeast probiotics without medical supervision. Concurrent use with antifungal medications such as fluconazole or itraconazole may reduce or eliminate the strain's viability and efficacy. Safety data during pregnancy and lactation specific to the CNCM I-1079 strain is insufficient, and consultation with a healthcare provider is recommended before use in these populations.